News Agency
Men's Weekly

First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH

  • Written by PR Newswire

SHANGHAI, April 2, 2024 /PRNewswire/ -- YolTech Therapeutics announced that the first patient has been dosed with YOLT-101, the company's in vivo genome editing candidate being developed as a single dose, potentially curative therapy for Familial Hypercholesterolemia(FH), marking the commencement of an Investigator-Initiated Trial (IIT).

Familial...

Read more: First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH

Understanding Your Rights Around Property After Separation

Property division is one of the most significant financial matters that arises when a relationship ends, and it's also one of the most commonly misunderstood. Many people assume that assets are simply divided equally, but the reality under Australian family... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion